Best Life Sciences Platforms and Tools Companies in United Kingdom
The 528 best Life Sciences Platforms and Tools companies in United Kingdom in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Nanopore Technologies.
The 528 Life Sciences Platforms and Tools companies tracked in the United Kingdom represent a serious slice of a global market forecast to reach $183.8B by 2027, growing at a 10.8% CAGR. That's not hype. That's the structural backdrop you're working with when you scan this directory. Nanopore Technologies leads the field with $1.3B in disclosed funding, a figure that dwarfs the rest of the cohort by a wide margin. Bit.bio has pulled in $186M, Nuclera $164M, and even the mid-tier names like Engitix ($60M) and Lightcast ($49M) signal that investors here are writing real checks, not speculative ones.
So what's driving the momentum? Quantitative accuracy improvements and advances in information sciences are pulling institutional capital toward platforms that can demonstrate measurable performance gains, not just promising pipelines. Regulatory challenges remain a friction point, and I'd argue they're actually sorting the field in useful ways, pushing better-capitalized, more credible operators to the front. With $4.5B in total disclosed funding across the directory and one unicorn already on the board, the UK's life sciences tools ecosystem is earning its reputation the hard way. Check the funding figures. They tell you where conviction actually sits.
- Precedence Research
Our analysis of 50 Life Sciences Platforms and Tools companies
$4.8b in tracked funding; 68% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences Platforms and Tools companies in United Kingdom
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Nanopore Technologies Manufacturer of portable and benchtop devices for real-time DNA sequencing 87Tech top 11%Market top 21%Funding top 21%Talent top 24% All 9 signals ▾Techtop 11% Markettop 21% Fundingtop 21% Talenttop 24% Newstop 32% Growthtop 39% Moattop 39% Globaltop 42% Fin. healthtop 47% Tech: 82 technologies across 7/8 capability areas · Cloud: Amazon Cloudfront, Amazon S3 Market: 705 employees (top 2% of High Tech) · Revenue ~$234M rank vs industry peers · Fliar Intelligence Index 87/100 | $1.3B | 22 mo ago | 705 705 → 1,352 (+92%) · sector median +16% | 2005 | Hagan Bayley Co-Founder | 13 signals ▲62% Leadership · Earnings | — | 1 launch |
| 2 | Rapid Micro Biosystems Developer of biosystems for microbial contamination detection | $350M | 63 mo ago | 202 202 → 204 (+1%) · sector median +16% | 2006 | Robert Spignesi President and CEO | 6 signals ▼62% Earnings · Capital raise | — | 2 launchs |
| 3 | Oribiotech 🦄 Biotech company focused on advancing cell and gene therapy manufacturing through innovative automation tool | $281M | 47 mo ago | 11 | 2015 | Farlan Veraitch Co-Founder & Chief Scientific Officer | — | 252 patents Design and optimization of bioreactor systems for cell culture and bioprocessing | 1 launch · 1 partnership |
| 4 | Bit.bio Manufacturer of programmed human cells for research and drug discovery 74Growth top 17%Funding top 23%News top 29%Moat top 31% All 9 signals ▾Growthtop 17% Fundingtop 23% Newstop 29% Moattop 31% Fin. healthtop 38% Talenttop 38% Markettop 44% Techbottom 48% Globalbottom 39% Growth: Headcount 13 → 52 (+300%) across vintages · Revenue +41% YoY Funding: Raised $186M across 7 rounds · 7 rounds over 9 yrs (0.8/yr) rank vs industry peers · Fliar Intelligence Index 74/100 | $186M | 5 mo ago | 52 | 2016 | Mark Kotter Co-Founder | 4 signals ▲300% Funding · Layoffs | — | 3 launchs |
| 5 | Nuclera Provider of rapid protein expression and screening systems for biotechnology labs 72Patents top 15%Innovation top 17%Funding top 26%Moat top 26% All 11 signals ▾Patentstop 15% Innovationtop 17% Fundingtop 26% Moattop 26% Growthtop 27% Talenttop 38% Techtop 42% Fin. healthtop 44% Newsbottom 44% Globalbottom 44% Marketbottom 40% Patents: 140 patents matched (strict assignee match) · 140 filings since 2022 vs 0 in 2017-21 Innovation: 140 patents (top 20% of patent-holders) · 140 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 72/100 | $164M | 6 mo ago | 26 | 2013 | Michael Chen Co-Founder & CEO | 3 signals ▼40% Capital raise · Funding | 140 patents Enables high-throughput protein assays on digital microfluidic platforms. | 2 job openings |
| 6 | MiroBio Developer of therapeutics for auto-immune diseases | $132M | 47 mo ago | 29 | 2019 | Simon Davis Co-Founder | — | 69 patents Therapeutic antibodies targeting BTLA and CD200R immune checkpoint proteins. | — |
| 7 | Catapult Cell and Gene Therapy Works as an accelerator for new technologies and ideas | $127M | 64 mo ago | 164 | 2012 | — | — | — | — |
| 8 | ONI Biotechnology company specializing in super-resolution microscopy systems | $113M | 53 mo ago | 143 | 2016 | Achillefs Kapanidis Co-Founder | — | — | 3 launchs |
| 9 | Enara Bio Developer of T-cell based cancer-cell interface for therapeutics | $84M | 20 mo ago | 38 38 → 68 (+79%) · sector median +16% | 2016 | Kevin Pojasek CEO & President | — | 63 patents Bispecific polypeptide therapeutics targeting novel cancer antigens for immunotherapy | — |
| 10 | Abcam Developer of biological reagents for life science research | $79M | 85 mo ago | 1,587 1,587 → 1,879 (+18%) · sector median +16% | 1998 | Tony Kouzarides Co-Founder | — | 39 patents Recombinant rabbit monoclonal antibodies for epigenetic (m6A) detection | — |
| 11 | Phoremost Developer of a phenotypic screening platform for drug target discovery | $77M | 21 mo ago | 32 32 → 33 (+3%) · sector median +16% | 2015 | Chris Torrance Founder & Chair at PhoreMost Ltd | — | 32 patents Discovery of peptide binders to ubiquitin E3 ligases and VCP inhibition | — |
| 12 | Constructive Bio Provider of a platform for genome and polymer synthesis | $75M | 14 mo ago | 3 | 2022 | Ola Wlodek CEO | — | — | 2 job openings · 1 award |
| 13 | Evonetix Developer of synthetic biology platform | $67M | 40 mo ago | 49 | 2015 | Raymond Edgson ex-Founder | — | 92 patents Automated DNA synthesis, enzymatic processing, and DNA-based data storage platforms. | — |
| 14 | Engitix Developer of technology for in vitro drug discovery 42Growth top 35%Talent top 38%Funding top 39%News top 43% All 10 signals ▾Growthtop 35% Talenttop 38% Fundingtop 39% Newstop 43% Patentstop 44% Moattop 47% Techtop 50% Innovationbottom 43% Globalbottom 42% Marketbottom 32% Growth: Fresh capital in last 24 mo Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 42/100 | $60M | 5 mo ago | 16 | 2016 | Massimo Pinzani Co-Founder | — | 4 patents Patents concentrated in chemistry & materials | 1 partnership |
| 15 | Sphere Fluidics Developer of Single-cell analysis systems for biologics discovery | $57M | 55 mo ago | 29 | 2010 | — | — | 114 patents Microfluidic droplet generation and manipulation for high-throughput biological assays. | — |
| 16 | Lightcast Developer of single-cell functional analysis using a droplet-based platform 35Funding top 28%Growth top 36%Talent top 38%Moat bottom 48% All 8 signals ▾Fundingtop 28% Growthtop 36% Talenttop 38% Moatbottom 48% Techbottom 46% Globalbottom 39% Marketbottom 30% Fin. healthbottom 22% Funding: Raised $49.0M across 7 rounds · 7 rounds over 3 yrs (2.3/yr) Growth: Headcount 10 → 25 (+150%) across vintages · Revenue -5% YoY rank vs industry peers · Fliar Intelligence Index 35/100 | $49M | 2 mo ago | 25 | 2019 | Cameron Frayling Founder | — | — | — |
| 17 | Portal Biotech Developer of biosensing technology that utilizes bioengineered nanopores to analyze proteins and metabolomics | $45M | 14 mo ago | — | 2021 | Giovanni Maglia Co-Founder | — | 13 patents Nanopore-based biomolecular sensing and protein/ analyte detection technologies. | — |
| 18 | CN Bio Develops organ-on-a-chip platforms for drug discovery | $45M | 25 mo ago | 33 33 → 59 (+79%) · sector median +16% | 2009 | Paul Brooks Chief Executive Officer | — | — | — |
| 19 | Cellular Origins Provider of automated manufacturing solution for cell and gene therapy 53Patents top 31%Innovation top 32%Funding top 34%Growth top 35% All 10 signals ▾Patentstop 31% Innovationtop 32% Fundingtop 34% Growthtop 35% Moattop 38% Techtop 46% Talentbottom 49% Globalbottom 40% Marketbottom 32% Newsbottom 17% Patents: 39 patents matched (strict assignee match) · 39 filings since 2022 vs 0 in 2017-21 Innovation: 39 patents (top 53% of patent-holders) · 39 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 53/100 | $40M | 6 mo ago | — | 2022 | Edwin Stone Founder & CEO | — | 39 patents Single-use bioprocessing hardware: bag cartridges, automated fluid handling, peristaltic pumps. | 1 launch · 1 partnership |
| 20 | OXGENE Provider of a platform for mammalian cell engineering | $27M | 11 mo ago | 102 | 2011 | Len Seymour Co-Founder | — | — | — |
| 21 | Jellagen Provider of medical-grade collagen type for life science research | $21M | 42 mo ago | 13 13 → 15 (+15%) · sector median +16% | 2013 | Alex Muhlholzl Co-Founder & CTO | — | 28 patents Marine-derived collagen extraction and biomedical formulation technologies | — |
| 22 | uMed Provider of platform facilitating patient data access for life science research | $17M | 35 mo ago | 11 | 2018 | Matt Wilson Founder & CEO | — | — | 1 job opening |
| 23 | Newcells Biotech Developer of induced pluripotent stem cells derived organoid models for research application | $17M | 18 mo ago | 20 20 → 13 (-35%) · sector median +16% | 2014 | — | — | 19 patents Microfluidic platforms for stem‑cell‑derived retinal and airway organoid culture | 1 award |
| 24 | Eden Research Sustainable biopesticides and plastic-free encapsulation technology for crop protection and animal health | $15M | 32 mo ago | 11 | 2003 | — | — | 134 patents Encapsulated high‑potency terpene agro‑chemicals for nematode control and crop protection | — |
| 25 | Phase Focus Provider of virtual lens that generates High definition images without high-quality lenses | $12M | 33 mo ago | 10 | 2006 | Martin Humphry Chief Executive Officer | — | 135 patents Object tracking and temporal behavior analysis in 3D imaging systems. | — |
| 26 | Cellvoyant Developer of AI-driven cell analytics platform and process optimisation services | $12M | 31 mo ago | 4 | 2021 | Rafael Carazo Salas Founder & CEO | — | — | 2 launchs · 2 partnerships |
| 27 | Iota Sciences Tools for fluidic science | $12M | 22 mo ago | 18 18 → 15 (-17%) · sector median +16% | 2016 | Peter Cook Co-Founder | — | — | — |
| 28 | ProteinLogic Biomarker discovery and exploitation platform | $11M | 28 mo ago | — | 2003 | Nicolas Huber CEO | — | 14 patents Discovery and application of protein biomarkers for disease diagnosis, notably tuberculosis. | — |
| 29 | Axol Bioscience Provider of human cells, reagents, and reprogramming services 48Growth top 34%Funding top 38%Moat top 39%Tech top 44% All 8 signals ▾Growthtop 34% Fundingtop 38% Moattop 39% Techtop 44% Talentbottom 49% Globalbottom 43% Marketbottom 38% Newsbottom 27% Growth: Headcount 24 → 29 (+21%) across vintages · 1 acquisition/expansion move in 24 mo Funding: Raised $10.5M across 9 rounds · 9 rounds over 12 yrs (0.8/yr) rank vs industry peers · Fliar Intelligence Index 48/100 | $10M | 5 mo ago | 29 29 → 61 (+110%) · sector median +16% | 2013 | Liam Taylor CEO | — | — | 1 award |
| 30 | RwHealth Provider of an AI-based drug discovery platform | $10M | 24 mo ago | 23 | 2011 | Scott Fletcher CEO | — | — | — |
| 31 | SkinBioTherapeutics Provider of probiotic lysates for the treatment of skin disease | $9M | 22 mo ago | 7 | 2015 | Stuart Ashman CEO | 16 signals Leadership · Board · Earnings | 27 patents Probiotic‑based skin‑care compositions and methods for skin repair. | — |
| 32 | Tozaro Provider of reagents for life science research and drug development 22Talent top 38%Patents top 42%Funding bottom 47%Innovation bottom 46% All 7 signals ▾Talenttop 38% Patentstop 42% Fundingbottom 47% Innovationbottom 46% Globalbottom 43% Techbottom 40% Marketbottom 25% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated Patents: 7 patents matched (strict assignee match) · 7 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 22/100 | $8M | 4 mo ago | — | 2015 | Stephane Argivier CEO | — | 7 patents Molecular diagnostics for viral RNA and enzyme‑control reagents for polymerase assays | — |
| 33 | Carcinotech Developer of 3D cancer research models for cancer drug discovery | $8M | 28 mo ago | 1 | 2018 | Ishani Malhotra CEO | — | 10 patents In‑vitro cancer model and microenvironment culture devices for tumor research | — |
| 34 | Cytomos POC cell sorter | $7M | 18 mo ago | 8 | 2012 | David Rigterink CEO | — | 32 patents Cellular analysis and biosensing instruments for measuring biological samples | — |
| 35 | Microsaic Systems Developer of MEMS-based mass spectrometry systems | $6M | 29 mo ago | 22 | 2001 | Eric Yeatman Consultant And Co-Founder | — | 180 patents Ion funnel and plasma ionisation technologies enhancing liquid sample mass spectrometry performance. | — |
| 36 | Chromacity Provider of tunable fiber lasers for industrial applications | $5M | 22 mo ago | 12 | 2013 | — | — | — | — |
| 37 | 4D Medicine Company specializes in research, development, and commercialization of transformative gene therapeutic… | $4M | 22 mo ago | — | 2018 | Andrew Dove Founder | — | 16 patents Biodegradable polymer drug‑delivery resins and tunable biocompatible materials for medical applications | — |
| 38 | Imperagen Developer of enzyme engineering platform for drug development 16Talent top 28%Funding top 49%Tech bottom 44%Global bottom 29% All 5 signals ▾Talenttop 28% Fundingtop 49% Techbottom 44% Globalbottom 29% Marketbottom 17% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $4.3M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 16/100 | $4M | 0 mo ago | 5 | 2021 | Timothy Eyes Co-Founder | — | — | — |
| 39 | ReadyGo Provider of diagnostic test and sample collection tools for research labs | $3M | 15 mo ago | 8 | 2020 | Elaine Warburton Co-Founder | — | — | — |
| 40 | Semarion Provider of a platform for drug discovery and screening | $3M | 2 mo ago | 3 | 2018 | Jeroen Verheyen Co-Founder & CEO | — | 4 patents Patents concentrated in computing, sensing & instrumentation | — |
| 41 | Abselion Provider of a benchtop instrument for protien research | $3M | 19 mo ago | 10 | 2018 | Ruizhi Wang Founder & CEO | — | — | — |
| 42 | NCIMB Provider of biorepository, microbial culture collection and microbiology services | $2M | 13 mo ago | 25 | 1982 | — | — | 2 patents Enzymatic synthesis of cyclodextrins using cyclodextrin glucanotransferase | — |
| 43 | Argonaute RNA Provider of RNA-based therapeutics | $2M | 23 mo ago | 7 | 2015 | Anthony Parker CEO | — | 46 patents Patents concentrated in chemistry & materials | — |
| 44 | ProAxsis Developer of diagnostic test for the detection of respiratory conditions | $2M | 11 mo ago | 12 12 → 7 (-42%) · sector median +16% | 2013 | David Ribeiro CEO | — | — | — |
| 45 | Aelius Biotech Provider of in vitro and human trial models for gut research | $2M | 14 mo ago | 2 | 2018 | Peter Chater Co-Founder & CEO | — | 13 patents Patents concentrated in chemistry & materials | — |
| 46 | Aptamer Group Manufacturer of DNA and RNA nucleic acid aptamers for use in research & development | $2M | 11 mo ago | 19 19 → 47 (+147%) · sector median +16% | 2008 | — | 16 signals ▲220% Contracts · Earnings · Announcements | 4 patents Patents concentrated in computing, sensing & instrumentation | 3 launchs |
| 47 | OGI Bio Provider of a system for automation of routine microbial culturing | $2M | 12 mo ago | 8 | 2020 | Teuta Pilizota Co-Founder | — | — | — |
| 48 | CellRev Developer of cell cultivation technologies | $2M | 20 mo ago | 17 | 2019 | Martina Miotto Co-Founder & Chief Scientific Officer | — | — | — |
| 49 | Atelerix Develops technology for storage and transportation of cells | $1M | 16 mo ago | 9 | 2017 | Che Connon Co-Founder | — | 11 patents Biopreservation and transport of extracellular nucleic acids, epitopes, and multicellular aggregates | 3 launchs · 1 award |
| 50 | Invenirex Developer of nucleic acid detection instruments | $637K | 6 mo ago | — | 2021 | Dan Todd Founder & CEO | — | — | 1 job opening |
Top 12 Life Sciences Platforms and Tools companies in United Kingdom
#1
Series C · Cambridge, England · founded 2016 · 52 employees$186.1Mraised▾
Manufacturer of programmed human cells for research and drug discovery. This entity utilizes gene-targeting technology to express transcription factors that reprogram induced pluripotent stem cells into defined human cell types. These products include various nerve, immune, and muscle cell lines designed for use in laboratory assays, disease modeling, and therapeutic development. The technology enables the production of consistent cell models for applications such as CRISPR screening, electrophysiology, and immunocytochemistry.
- Jan 2026Series C$50M
- Dec 2024Series B$30M
- Dec 2021Series B$37.2M
- Sep 2021Series B$103M
#2
Series B · Cambridge, England · founded 2019 · 25 employees$49Mraised▾
Developer of single-cell functional analysis using a droplet-based platform. The technology uses light rays to precisely control picoliter-scale droplets, enabling scalable assays for drug discovery, therapeutics, and basic research. The system facilitates sequential assays and the real-time dispensing of cells for downstream applications. It supports research into biomolecule secretion, cell-cell communication, and targeted cell killing mechanisms. The platform allows for the precise control of droplet merging to characterize individual cell responses.
- Apr 2026Series B$27M
- Aug 2023Series B$49M
- Dec 2022Series B$25.1M
- Mar 2022Series A$14.2M
#3
Series C · Cambridge, England · founded 2013 · 26 employees$164.2Mraised▾
Provider of rapid protein expression and screening systems for biotechnology labs. It helps life science researchers rapidly prototype, screen, and optimize protein expression. The system uses cell-free synthesis, digital microfluidics, and automated workflows to deliver reliable protein access in days rather than months, supporting research, characterization, and scale-up in biotech and pharma labs.
- Dec 2025Series C$12M
- Oct 2024Series C$75M
- Jun 2024Grant (prize money)$1.5M
- Nov 2023Series B—
#4
Series A · London, England · founded 2016 · 16 employees$60.4Mraised▾
Developer of technology for in vitro drug discovery. The company's proprietary technology includes a human-derived biological scaffold for the development of 3D spheroids and tissue engineering systems. The applications of the technology include accelerating in vitro drug discovery and helping patients with end-stage liver disease. The company has also designed BAL to address the unmet need for treatment of liver failure, providing bedside support.
- Jan 2026Series A$25M
- Jan 2022Series A$54M
- Nov 2018Series A$6.4M
#5
Public · Oxford, England · founded 2005 · 705 employees$1.3Braised▾
Manufacturer of portable and benchtop devices for real-time DNA sequencing. These instruments utilize nanopore sensing technology to analyze native DNA and RNA molecules. The hardware supports various workflows, including library preparation and data analysis through integrated software tools. Applications include genomic research, microbial identification, and transcriptomics. The technology enables the detection of genetic variations and structural changes in biological samples.
- Aug 2024Post IPO$64.2M
- Oct 2023Post IPO$84.5M
- May 2021Series H$270.5M
- Oct 2020Series G$110.1M
#6
Series A · Melbourn, Cambridgeshire · founded 2022$40Mraised▾
Provider of automated manufacturing solution for cell and gene therapy. It offers Constellation a closed, configurable, robotic platform for the production of cell and gene therapy. It deliver GMP-compliant, full cell therapy automation for scaling cell therapy manufacturing.
- Dec 2025Series A$40M
#7
Seed · Manchester, England · founded 2021 · 5 employees$4.3Mraised▾
Developer of enzyme engineering platform for drug development. It offers enzyme products for the manufacture of complex drug molecules. It has applications in laboratory tools to enzyme replacement therapies and drug delivery systems.
- May 2026Seed$6.7M
- Aug 2022Seed$4.3M
#8
Series A · Cambridge, England · founded 2013 · 29 employees$10.5Mraised▾
Provider of human cells, reagents, and reprogramming services. The company's products include reprogramming cells and iPSCs. The company also provides differentiated cells derived from healthy donors and patients of specific disease backgrounds. It provides culture medium and reagents such as Xeno-Free Neural Cell Culture, Cell Culture Media, Coating Solutions, Reagents and Supplements, Cytokines, and Growth Factors.
- Jan 2026Series A$2.8M
- Apr 2022Series A$4.2M
- Apr 2021Series A$344.1K
- Oct 2020Grant (prize money)$366.9K
#9
Series A · Bedford, England · founded 2015$8.2Mraised▾
Provider of reagents for life science research and drug development. It offers smart polymer affinity reagents that offer novel analytics and purification solutions to enhance the development and manufacture of viral vectors in cell and gene therapy.
- Feb 2026Series A$8.2M
#10
Series A · Cambridge, England · founded 2018 · 3 employees$2.9Mraised▾
Provider of a platform for drug discovery and screening. The company focuses on drug screening and lead identification of GPCR-targeting oncology drugs. The company has developed the proprietary technology called SemaCyte which is the microchip technology and nanomagnetism that helps in drug discovery. It focuses on drug discovery which will target the cell surface receptors such as GPCRs and tyrosine kinases.
- Mar 2026Series A$3.8M
- Feb 2022Seed$2.9M
#11
Acquired · Oxford, England · founded 2011 · 102 employees$27.1Mraised▾
Provider of a platform for mammalian cell engineering. The company provides plasmid and DNA component products and a plasmid technology called SnapFast. The company is designing DNA sequences, optimizing the expression of proteins, developing cell lines, and improving viral delivery systems. It integrates bioinformatics and gene-editing technology to create a streamlined workflow for cell line production.
- Jul 2025Series A$1M
- May 2020Series A$3.7M
- Mar 2019Series A$8.6M
- Aug 2017Series A$10.3M
#12
Series A · Saffron Walden, England · founded 2022 · 3 employees$75Mraised▾
Provider of a platform for genome and polymer synthesis. The company pioneered the development of methods for reprogramming the genetic code of living organisms that are resistant to a wide variety of viruses, can be programmed to make synthetic, polymers, and even perform entirely new functions. It has applications across a range of industries including novel therapeutics and antibiotics enhanced agriculture, manufacturing, and materials.
- Mar 2025Series A—
- Sep 2024Series A$58M
- Aug 2022Seed$15M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences Platforms and Tools coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics is moving in the United Kingdom
A read on the academic research around Bioinformatics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 3,509 United Kingdom-affiliated papers.
- European Bioinformatics Institute204
- University of Cambridge194
- University of Oxford193
- University College London180
- Imperial College London179
- Genome27→142
- Gene20→131
- Transcriptome5→84
- Disease2→62
- Immune system1→44
- Disease4→116
- Gene6→81
- Cancer6→46
- Genome10→43
- Phenotype1→27
- Disease7→79
- Cancer4→28
- Immune system2→25
- Context (archaeology)3→22
- Genome5→21
Where bioinformatics is researched across United Kingdom
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing bioinformatics patents in the United Kingdom
United Kingdom bioinformatics patent filing is cooling — 19 filings from 7 assignees (2016–2025), led by Deepmind TECH, BISN Laboratory Services, Gardner Steve; annual filings 5→2.
- Deepmind TECH13
- BISN Laboratory Services3
- Gardner Steve1
- Lemon1
- BISN LAB Services1
- Samsung1
- Beijing Youzhuju Network TECH1
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.